Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Kerri A Johannson; Irina Strâmbu; Claudia Ravaglia; Jan C Grutters; Claudia Valenzuela; Nesrin Mogulkoc; Fabrizio Luppi; Luca Richeldi; Athol U Wells; Carlo Vancheri; Michael Kreuter; Carlo Albera; Katerina M. Antoniou; Goksel Altinisik; Elisabeth Bendstrup; Benjamin Bondue; Raphael Borie; Kevin K. Brown; Philippe Camus; Diego Castillo; Harold R. Collard; Vincent Cottin; Nunzio Crimi; Giovanni Ferrara; Aryeh Fischer; Jack Gauldie; Thomas Geiser; Andreas Guenther; Nathan Hambly; David M. Hansell; Sergio Harari; Mark G. Jones; Michael Keane; Brett Ley; Toby M. Maher; Maria Molina-Molina; Stefano Palmucci; Venerino Poletti; Antje Prasse; Paola Rottoli; Paolo Spagnolo; Martina Sterclova; Sebastiano Torrisi; Eliza Tsitoura; Martina Vasakova; Simon L. Walsh; Marlies S. Wijsenbeek; Wim A. Wuyts

doi:10.1016/S2213-2600(17)30219-9

Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Kerri A Johannson, Irina Strâmbu, Claudia Ravaglia, Jan C Grutters, Claudia Valenzuela, Nesrin Mogulkoc, Fabrizio Luppi, Luca Richeldi, Athol U Wells, Carlo Vancheri, Michael Kreuter, Carlo Albera, Katerina M. Antoniou, Goksel Altinisik, Elisabeth Bendstrup, Benjamin Bondue, Raphael Borie, Kevin K. Brown, Philippe Camus, Diego CastilloHarold R. Collard, Vincent Cottin, Nunzio Crimi, Giovanni Ferrara, Aryeh Fischer, Jack Gauldie, Thomas Geiser, Andreas Guenther, Nathan Hambly, David M. Hansell, Sergio Harari, Mark G. Jones, Michael Keane, Brett Ley, Toby M. Maher, Maria Molina-Molina, Stefano Palmucci, Venerino Poletti, Antje Prasse, Paola Rottoli, Paolo Spagnolo, Martina Sterclova, Sebastiano Torrisi, Eliza Tsitoura, Martina Vasakova, Simon L. Walsh, Marlies S. Wijsenbeek, Wim A. Wuyts

Risultato della ricerca: Contributo in rivista › Articolo in rivista

43 Citazioni (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.

Lingua originale	English
pagine (da-a)	591-598
Numero di pagine	8
Rivista	The Lancet Respiratory Medicine
Volume	5
DOI	https://doi.org/10.1016/S2213-2600(17)30219-9
Stato di pubblicazione	Pubblicato - 2017

Keywords

Antacids
Disease Progression
Gastroesophageal Reflux
Histamine H2 Antagonists
Humans
Idiopathic Pulmonary Fibrosis
Practice Guidelines as Topic
Proton Pump Inhibitors
Pulmonary and Respiratory Medicine
Risk Factors
Severity of Illness Index

Accesso al documento

10.1016/S2213-2600(17)30219-9

Altri file e collegamenti

Cita questo

Johannson, K. A., Strâmbu, I., Ravaglia, C., Grutters, J. C., Valenzuela, C., Mogulkoc, N., Luppi, F., Richeldi, L., Wells, A. U., Vancheri, C., Kreuter, M., Albera, C., Antoniou, K. M., Altinisik, G., Bendstrup, E., Bondue, B., Borie, R., Brown, K. K., Camus, P., ... Wuyts, W. A. (2017). Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? The Lancet Respiratory Medicine, 5, 591-598. https://doi.org/10.1016/S2213-2600(17)30219-9

@article{26d2ff32594246619da4efe204b53b1b,

title = "Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?",

abstract = "Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.",

keywords = "Antacids, Disease Progression, Gastroesophageal Reflux, Histamine H2 Antagonists, Humans, Idiopathic Pulmonary Fibrosis, Practice Guidelines as Topic, Proton Pump Inhibitors, Pulmonary and Respiratory Medicine, Risk Factors, Severity of Illness Index, Antacids, Disease Progression, Gastroesophageal Reflux, Histamine H2 Antagonists, Humans, Idiopathic Pulmonary Fibrosis, Practice Guidelines as Topic, Proton Pump Inhibitors, Pulmonary and Respiratory Medicine, Risk Factors, Severity of Illness Index",

author = "Johannson, {Kerri A} and Irina Str{\^a}mbu and Claudia Ravaglia and Grutters, {Jan C} and Claudia Valenzuela and Nesrin Mogulkoc and Fabrizio Luppi and Luca Richeldi and Wells, {Athol U} and Carlo Vancheri and Michael Kreuter and Carlo Albera and Antoniou, {Katerina M.} and Goksel Altinisik and Elisabeth Bendstrup and Benjamin Bondue and Raphael Borie and Brown, {Kevin K.} and Philippe Camus and Diego Castillo and Collard, {Harold R.} and Vincent Cottin and Nunzio Crimi and Giovanni Ferrara and Aryeh Fischer and Jack Gauldie and Thomas Geiser and Andreas Guenther and Nathan Hambly and Hansell, {David M.} and Sergio Harari and Jones, {Mark G.} and Michael Keane and Brett Ley and Maher, {Toby M.} and Maria Molina-Molina and Stefano Palmucci and Venerino Poletti and Antje Prasse and Paola Rottoli and Paolo Spagnolo and Martina Sterclova and Sebastiano Torrisi and Eliza Tsitoura and Martina Vasakova and Walsh, {Simon L.} and Wijsenbeek, {Marlies S.} and Wuyts, {Wim A.}",

year = "2017",

doi = "10.1016/S2213-2600(17)30219-9",

language = "English",

volume = "5",

pages = "591--598",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Ltd",

}

Johannson, KA, Strâmbu, I, Ravaglia, C, Grutters, JC, Valenzuela, C, Mogulkoc, N, Luppi, F, Richeldi, L, Wells, AU, Vancheri, C, Kreuter, M, Albera, C, Antoniou, KM, Altinisik, G, Bendstrup, E, Bondue, B, Borie, R, Brown, KK, Camus, P, Castillo, D, Collard, HR, Cottin, V, Crimi, N, Ferrara, G, Fischer, A, Gauldie, J, Geiser, T, Guenther, A, Hambly, N, Hansell, DM, Harari, S, Jones, MG, Keane, M, Ley, B, Maher, TM, Molina-Molina, M, Palmucci, S, Poletti, V, Prasse, A, Rottoli, P, Spagnolo, P, Sterclova, M, Torrisi, S, Tsitoura, E, Vasakova, M, Walsh, SL, Wijsenbeek, MS & Wuyts, WA 2017, 'Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?', The Lancet Respiratory Medicine, vol. 5, pagg. 591-598. https://doi.org/10.1016/S2213-2600(17)30219-9